Confirming a KIT mutation and assessing disease spread are critical initial steps for GIST management. Understanding the mutational profile helps tailor treatment, as some mutations may resist Gleevec ...
Combining surgery with chemotherapy significantly improves survival in GIST patients with liver metastases compared to chemotherapy alone. Median CSS and OS for combined treatment exceed 120 months, ...
Mixed liposarcoma: A study of socioeconomic and demographic factors. 5-year overall survival rates by time period and stage for GIST and STS.
Cogent Biosciences, Inc. soared 120% after positive Phase 3 PEAK study results for bezuclastinib in imatinib-resistant GIST patients. COGT's bezuclastinib showed a 50% reduction in disease progression ...
A recent study offering a comprehensive view of the genome and transcriptome of gastrointestinal stromal tumors (GISTs) has introduced a new, multi-omics-based molecular classification of these tumors ...
Gastrointestinal stromal tumors (GISTs) have increased in incidence over the past two decades, with notable survival disparities among racial and ethnic groups, particularly among Black patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results